You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
華潤醫藥(03320.HK):東阿阿膠一季度淨利潤預增92%-114%

格隆匯4月13日丨華潤醫藥(03320.HK)發佈公吿,2023年4月12日,東阿阿膠(000423.SZ)公佈2023年第一季度業績預吿,報吿期歸屬於東阿阿膠的淨利潤人民幣2.20億元–2.45億元,同比增長92%-114%;扣除非經常性損益後的淨利潤2.06億元–2.20億元,同比增長125%-140%;基本每股收益盈利0.34元/股–0.38元/股。

2023年圍繞“增長 · 效率”關鍵主題,進一步推進價值重塑,加速業務重塑,深化組織重塑,抓實精神重塑。持續鞏固“滋補國寶東阿阿膠”頂流品牌地位,堅持以消費者為中心,深入做好“藥品” “健康消費品”雙輪驅動,科學創新研發佈局,繼續夯實阿膠塊和複方阿膠漿基石業務角色,啟動複方阿膠漿大品種戰略,拓展桃花姬阿膠糕區域佈局,經營業績穩步提升。

未來,東阿阿膠將在雙輪驅動模式指引下,充分把握中醫藥發展新機遇,大力弘揚中醫藥傳統文化,系統構築循證醫學學術體系,着力引領阿膠品類升級,健全完善滋補品類佈局,持續豐富“阿膠+” “+阿膠”產品拓展,全面推動東阿阿膠組織能力及系統能力重構,致力於成為滋補健康行業引領者。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account